Innovator US Equity Ultra Buffer ETF - Nov | 10-Q: FY2026 Q2 Revenue: USD 9.051 M

LB filings

2025.11.12 11:34

I'm PortAI, I can summarize articles.

Revenue: As of FY2026 Q2, the actual value is USD 9.051 M.

EPS: As of FY2026 Q2, the actual value is USD 0.003.

EBIT: As of FY2026 Q2, the actual value is USD 588.21 K.

Total Revenue: For the six months ended September 30, 2025, total revenue was $17,810,816, an increase from $17,087,965 in the same period in 2024, representing a 4% increase.
Revenue by Segment:
- Sale of Pharmaceutical products – RxCompound: $15,688,808 for the six months ended September 30, 2025, compared to $16,972,729 in 2024.
- Sale of Pharmaceutical products – Peaks: $1,122,974 for the six months ended September 30, 2025, compared to $115,236 in 2024.
- Sale of products and services – Villas Health: $227,144 for the six months ended September 30, 2025, with no comparable revenue in 2024.

Gross Profit: For the six months ended September 30, 2025, gross profit was $12,814,758, compared to $12,677,115 in 2024, representing a gross margin of 71% in 2025, down from 74% in 2024.
Net Income: For the six months ended September 30, 2025, net income was $1,402,611, compared to $1,874,622 in 2024.

Operating Cash Flow: Net cash provided by operating activities for the six months ended September 30, 2025, was $1,181,196, compared to $1,877,917 in the same period in 2024.
Investing Cash Flow: Net cash used in investing activities was - $940,788 for the six months ended September 30, 2025.
Financing Cash Flow: Net cash used in financing activities was - $478,262 for the six months ended September 30, 2025.

Core Business Focus: The company plans to expand its telemedicine services nationwide through Peaks and increase its market presence by acquiring new business units, as evidenced by the acquisition of Zoolzy.com for veterinary services.
Non-Core Business: The company is actively pursuing a $5 million share repurchase program managed by Avenvi, indicating a focus on optimizing shareholder value.